News
In 2025, you can binge on nachos, chase it with a weight loss shot—welcome to diet culture’s latest contradiction. Every year ...
Hims asked Americans to weigh in on their favorite junk foods, and what we learned is that America’s palette is as diverse as ...
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...
Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...
Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...
Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at ...
1d
MarketBeat on MSNWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...
Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.
Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results